Myeloproliferative Neoplasms Clinical Trial

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET

Summary

A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Ropeginterferon alfa-2b-njft (P1101) in Adult Patients with Essential Thrombocythemia

View Full Description

Full Description

PharmaEssentia is developing a pegylated (PEG) IFN-α product, P1101, for the treatment of Essential Thrombocythemia (ET) as lack of disease modifying therapies in essential ET constitutes a serious issue in modern hematology.

Ropeginterferonalfa-2b-njft (P1101) may represent an effective, well-tolerated treatment with the ability to provide a deeper response and superior control of important blood parameters with the potential to alter the course of the disease and prevent progression to post-ET myelofibrosis (MF) and/or secondary acute myeloid leukemia (sAML). Ropeginterferon alfa-2b-njft (P1101) is currently being evaluated in comparison to ANA in the ongoing global Phase 3 clinical study, SURPASS ET..

Enrolled patients will receive P1101 over 13 months followed by an extension period.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Male and female subjects ≥18 years old.
Subjects diagnosed with ET according to the World Health Organization (WHO) 2016 criteria.
Subjects that are cytoreductive treatment-naïve, or pre-exposed to HU and/or ANA, as specified below (according to Investigator's judgment and documented in the patient's medical record):
Interferon treatment-naïve.
Adequate hepatic function defined as bilirubin ≤1.5 × upper limit normal (ULN), prothrombin time (PT) (international normalized ratio, [INR]) ≤1.5 x ULN, albumin >3.5 g/dL, alanine aminotransferase (ALT) ≤2.0 x ULN, aspartate aminotransferase ≤2.0 x ULN at screening.
Creatinine clearance ≥40 mL/min (by Cockcroft-Gault equation).
Males and females of childbearing potential, as well as all women <2 years after the onset of menopause, must agree to use an acceptable form birth control until 60 days following last dose study drug, and females not breastfeed during study.
Written informed consent obtained from the subject and ability for the subject to comply with the requirements of the study.
Platelet count >450 × 109/L at screening

Exclusion Criteria:

Any subject requiring a legally authorized representative
Any contraindications or hypersensitivity to IFN-α and/or its excipients
Co-morbidity with severe or serious condition that, in the Investigator's opinion, would jeopardize the safety of the subject or their compliance with the protocol, including significant cardiac disease (including New York Heart Association Class III-IV congestive heart failure and clinically significant arrhythmias) and pulmonary hypertension
History of major organ transplantation
Pregnant or lactating females
Subjects with any significant medical conditions that, in the opinion of the Investigator, would compromise the results of the study or may impair compliance with the requirements of the protocol, including but not limited to:
Use of any investigational drug <4 weeks prior to the first dose of study drug or not recovered from effects administration any investigational agent
Presence of more than one driver mutation (e.g., V617F JAK2 and CALR, CALR and MPL, V617F JAK2 and MPL)
Prior use of Ruxolitinib

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 2

Estimated Enrollment:

64

Study ID:

NCT05482971

Recruitment Status:

Recruiting

Sponsor:

PharmaEssentia

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 20 Locations for this study

See Locations Near You

University of Alabama at Birmingham
Birmingham Alabama, 35294, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Mayo Clinic - Scottsdale
Scottsdale Arizona, 85054, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Marin Cancer Care
Greenbrae California, 94904, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Yale University School of Medicine - Yale Cancer Center
New Haven Connecticut, 06510, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
The Winship Cancer Institute Emory University
Atlanta Georgia, 30322, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
University of Kansas Cancer Center
Kansas City Kansas, 66160, United States More Info
Zachary prutch
Contact
800-999-2449
[email protected]
Tulane University Medical Center
New Orleans Louisiana, 70112, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Washington University School of Medicine - Division of Oncology
Saint Louis Missouri, 63110, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Cancer Care Specialists
Reno Nevada, 89511, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
John Theurer Cancer Center At Hackensack UMC
Hackensack New Jersey, 07601, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Montefiore Medical Center
Bronx New York, 10467, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Weill Medical College of Cornell University
New York New York, 10021, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
East Carolina University
Greenville North Carolina, 27858, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Cleveland Clinic
Cleveland Ohio, 44195, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
Fox Chase Cancer Center
Philadelphia Pennsylvania, 19111, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
University of Tennessee Health Science Center
Memphis Tennessee, 38103, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
MD Anderson Cancer Center
Houston Texas, 77030, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
University of Texas Health Science Center at San Antonio
San Antonio Texas, 78229, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
University of Utah
Salt Lake City Utah, 84132, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
University of Virginia - Emily Couric Cancer Center
Charlottesville Virginia, 22903, United States More Info
Zachary Prutch
Contact
800-999-2449
[email protected]
St. Paul's Hospital - Providence Health Care
Vancouver British Columbia, , Canada More Info
Zachary Prutch
Contact
1-800-999-2449
[email protected]
Juravinski Cancer Centre
Hamilton Ontario, , Canada More Info
Zachary Prutch
Contact
1-800-999-2449
[email protected]
Princess Margaret Hospital
Toronto Ontario, , Canada More Info
Zachary Prutch
Contact
1-800-999-2449
[email protected]

How clear is this clinincal trial information?

Study is for people with:

Myeloproliferative Neoplasms

Phase:

Phase 2

Estimated Enrollment:

64

Study ID:

NCT05482971

Recruitment Status:

Recruiting

Sponsor:


PharmaEssentia

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.